Dyne Therapeutics (DYN) Superinvestor holders
13 of the superinvestors we track hold Dyne Therapeutics (DYN) in their latest 13F filings, $92M in total.
Summary
The largest holder is Paul Marshall (Marshall Wace), with $33M, 0.0% of the portfolio.
In their latest quarter: 2 opened a new position, 4 added, 5 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Paul Marshall Marshall Wace |
Added | 1,488,917 | $33M | 0.0% | Q2 2026 |
| Artisan Partners | Added | 659,786 | $15M | 0.0% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Added | 415,131 | $9M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 360,572 | $8M | 0.0% | Q2 2026 |
| Louis Bacon Moore Capital Management |
Added | 305,794 | $7M | 0.2% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 289,730 | $6M | 0.0% | Q2 2026 |
| Wasatch Wasatch Global Investors |
Trimmed | 319,913 | $5M | 0.0% | Q3 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 259,024 | $4M | 0.0% | Q3 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 84,054 | $2M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
New position | 60,161 | $1M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Held | 37,214 | $826,523 | 0.0% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 18,000 | $399,780 | 1.9% | Q2 2026 |
| Two Sigma Two Sigma Investments |
New position | 14,178 | $314,893 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 13 |
| Q1 2026 | 16 |
| Q4 2025 | 15 |
| Q3 2025 | 13 |
| Q2 2025 | 12 |
| Q1 2025 | 11 |
| Q4 2024 | 13 |
| Q3 2024 | 11 |
Questions about Dyne Therapeutics
Which superinvestors own Dyne Therapeutics?
13 of the superinvestors we track hold Dyne Therapeutics (DYN) in their latest 13F filings, $92M in total. Paul Marshall, Artisan Partners, Hersh Cohen, Jim Simons, Louis Bacon, Ensign Peak.
Who is the largest superinvestor holder of DYN?
The largest holder is Paul Marshall (Marshall Wace), with $33M, 0.0% of the portfolio.
From Dyne Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.